We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for...
Communiqué de presse : Approbation du Sarclisa aux États-Unis : premier anti-CD38, en association avec un traitement conventionnel, pour les patients atteints d’un myélome multiple nouvellement...
Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for...
Communiqué de presse : Le CHMP recommande l’approbation du Dupixent dans l’UE pour le traitement de l’œsophagite à éosinophiles de l’enfant à partir de 12 mois Le CHMP recommande l’approbation...
Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Dupixent recommended for EU approval by the CHMP to treat...
Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a phase 3 study showing a significantly greater...
Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study Tolebrutinib...
CP : Le tolebrutinib a permis d’allonger de 31 % le délai avant progression confirmée du handicap dans le cadre d’une étude de phase III menée chez des personnes présentant une sclérose en plaques...
Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study Data presented at ECTRIMS show...
Sanofi: Informations relatives au nombre de droits de vote et d'actions - AOUT 2024 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.08 | 0.0772200772201 | 103.6 | 104.98 | 102.5 | 1872077 | 103.42853826 | DE |
4 | 2.72 | 2.6941362916 | 100.96 | 106.14 | 100.5 | 1618236 | 103.64856816 | DE |
12 | 12.02 | 13.113680995 | 91.66 | 106.14 | 89.77 | 1409016 | 98.15741844 | DE |
26 | 14.99 | 16.9015672567 | 88.69 | 106.14 | 85.07 | 1463386 | 93.45820576 | DE |
52 | 2.24 | 2.20820189274 | 101.44 | 106.14 | 80.6 | 1486287 | 91.75273888 | DE |
156 | 20.08 | 24.019138756 | 83.6 | 106.66 | 76.45 | 1773770 | 91.9956337 | DE |
260 | 19.68 | 23.4285714286 | 84 | 106.66 | 67.65 | 1972859 | 88.85274711 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions